Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma

    Summary
    EudraCT number
    2017-002423-19
    Trial protocol
    GB   DE   CZ   FR   ES   PL   IT  
    Global end of trial date
    14 Dec 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    28 Dec 2024
    First version publication date
    28 Dec 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    BGB-A317-301
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03412773
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    RATIONALE-301: BeiGene, JapicCTI-194569 : Japic, CTR20170882: ChinaDrugTrials
    Sponsors
    Sponsor organisation name
    BeiGene
    Sponsor organisation address
    1840 Gateway Drive, San Mateo, United States, 94404
    Public contact
    BeiGene Clinical Support, BeiGene, Inc., 1 877-828-5568, clinicaltrials@beigene.com
    Scientific contact
    BeiGene Clinical Support, BeiGene, Inc., 1 877-828-5568, clinicaltrials@beigene.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    14 Dec 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    14 Dec 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    This Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not be surgically removed. Before enrolling Japanese participants in the main Phase 3 study, a preliminary assessment of safety and tolerability (the Safety Run-In Sub study) was conducted in Japan.
    Protection of trial subjects
    This study was conducted in accordance with BeiGene procedures, which comply with the principles of Good Clinical Practice, International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use guidelines, the Declaration of Helsinki, and local regulatory requirements. The protocol, any amendments, and informed consent forms (ICFs) were reviewed and approved by the Independent Ethics Committee (IEC)/Institutional Review Board (IRB) in conformance with Good Clinical Practice and applicable regulatory requirements. The IEC/IRB-approved ICF was signed and dated by the patient or the patient’s legally authorized representative before his or her participation in the study
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    18 Dec 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    China: 411
    Country: Number of subjects enrolled
    Czechia: 3
    Country: Number of subjects enrolled
    Japan: 87
    Country: Number of subjects enrolled
    Taiwan: 14
    Country: Number of subjects enrolled
    United States: 19
    Country: Number of subjects enrolled
    Poland: 19
    Country: Number of subjects enrolled
    Spain: 15
    Country: Number of subjects enrolled
    United Kingdom: 10
    Country: Number of subjects enrolled
    France: 50
    Country: Number of subjects enrolled
    Germany: 19
    Country: Number of subjects enrolled
    Italy: 37
    Worldwide total number of subjects
    684
    EEA total number of subjects
    143
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    414
    From 65 to 84 years
    259
    85 years and over
    11

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The main study enrolled participants across Asia, Europe, and the U.S., with the first consented on December 18, 2017, and completion on December 14, 2023. A safety run-in sub-study in Japan assessed tislelizumab's safety in Japanese patients with hepatocellular carcinoma (HCC); these participants were not evaluated for the main study's endpoints.

    Pre-assignment
    Screening details
    The main study had four phases: Screening, Treatment, Safety Follow-up (up to 30 days post-treatment or 90 days post-tislelizumab for immune events), and Survival Follow-up (duration varied). Randomization was stratified by macrovascular invasion, extrahepatic spread, etiology, ECOG status (0 vs 1), and geography (Asia, Japan, Rest of World).

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Arm A: Tislelizumab
    Arm description
    Participants received 200 mg of intravenous tislelizumab every 3 weeks until intolerable toxicity, withdrawal of consent, or the investigator determined no further benefit from the therapy.
    Arm type
    Experimental

    Investigational medicinal product name
    Tislelizumab
    Investigational medicinal product code
    BGB-A317
    Other name
    Pharmaceutical forms
    Injection/infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Tislelizumab 200 mg intravenously (IV) once every three weeks (Q3W)

    Arm title
    Arm B: Sorafenib
    Arm description
    Participants received 400 mg of oral sorafenib twice daily until intolerable toxicity, consent withdrawal, or the investigator deemed no further benefit.
    Arm type
    Active comparator

    Investigational medicinal product name
    Sorafenib
    Investigational medicinal product code
    BAY43-9006
    Other name
    Nexavar
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Sorafenib 400 mg orally (PO) twice daily (BID)

    Arm title
    Safety Run-In Sub-study
    Arm description
    Japanese participants received 200 mg intravenous tislelizumab every 3 weeks to assess preliminary safety and tolerability.
    Arm type
    Safety Run-In Sub-study Arm

    Investigational medicinal product name
    Tislelizumab
    Investigational medicinal product code
    BGB-A317
    Other name
    Pharmaceutical forms
    Injection/infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Tislelizumab 200 mg intravenously (IV) once every three weeks (Q3W)

    Number of subjects in period 1
    Arm A: Tislelizumab Arm B: Sorafenib Safety Run-In Sub-study
    Started
    342
    332
    10
    Treated
    338
    324
    10
    Completed
    0
    0
    0
    Not completed
    342
    332
    10
         Consent withdrawn by subject
    15
    19
    -
         Physician decision
    -
    1
    -
         Death
    259
    273
    7
         Study Closed By Sponsor
    46
    33
    3
         Lost to follow-up
    7
    6
    -
         Transfer to LTE or Post Trial Supply
    15
    -
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Arm A: Tislelizumab
    Reporting group description
    Participants received 200 mg of intravenous tislelizumab every 3 weeks until intolerable toxicity, withdrawal of consent, or the investigator determined no further benefit from the therapy.

    Reporting group title
    Arm B: Sorafenib
    Reporting group description
    Participants received 400 mg of oral sorafenib twice daily until intolerable toxicity, consent withdrawal, or the investigator deemed no further benefit.

    Reporting group title
    Safety Run-In Sub-study
    Reporting group description
    Japanese participants received 200 mg intravenous tislelizumab every 3 weeks to assess preliminary safety and tolerability.

    Reporting group values
    Arm A: Tislelizumab Arm B: Sorafenib Safety Run-In Sub-study Total
    Number of subjects
    342 332 10 684
    Age categorical
    Units: Subjects
        18-64 years
    206 207 1 414
        65-84 years
    129 121 9 259
        >= 85 years
    7 4 0 11
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    60.45 ( 12.528 ) 59.51 ( 12.737 ) 71.70 ( 8.247 ) -
    Gender categorical
    Units: Subjects
        Female
    53 51 3 107
        Male
    289 281 7 577
    Eastern Cooperative Oncology Group (ECOG) Performance Status
    The ECOG scale assesses disease status from 0 to 5. A score of 0 means fully active with no restrictions, while 1 indicates limitations in strenuous activities but the ability to do light work. Score 2 signifies ambulatory and capable of self-care, yet unable to work, being active for over 50% of waking hours. Score 3 reflects limited self-care, confined to bed or a chair for more than half the day. Score 4 indicates complete disability, with the participant fully bedbound, and score 5 means deceased. Data are reported exclusively for participants in the main study.
    Units: Subjects
        Zero
    182 180 9 371
        One
    160 152 1 313
    Macrovascular Invasion
    Macrovascular invasion refers to the spread of cancer into large blood vessels near the tumor, and is associated with a more advanced stage of disease and a poorer prognosis. When present, cancer has infiltrated major blood vessels; when absent, no invasion into these vessels is detected, indicating a less aggressive disease.
    Units: Subjects
        Present
    51 48 0 99
        Absent
    291 284 10 585
    Extrahepatic Spread
    Extrahepatic spread refers to the spread of liver cancer beyond the liver to other organs or tissues. When present, cancer has metastasized outside the liver; when absent, the cancer is confined to the liver.
    Units: Subjects
        Present
    219 198 4 421
        Absent
    123 134 6 263
    Etiology
    Participants were grouped based on the presence of Hepatitis C virus or another virus, with those having both Hepatitis B and C classified under the "other" category.
    Units: Subjects
        Hepatitis C Virus
    46 39 4 89
        Other
    296 293 6 595
    Geographic Region
    Units: Subjects
        Asia Exluding Japan
    215 210 0 425
        Japan
    38 39 10 87
        European Union (EU)/United States (US)
    89 83 0 172

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Arm A: Tislelizumab
    Reporting group description
    Participants received 200 mg of intravenous tislelizumab every 3 weeks until intolerable toxicity, withdrawal of consent, or the investigator determined no further benefit from the therapy.

    Reporting group title
    Arm B: Sorafenib
    Reporting group description
    Participants received 400 mg of oral sorafenib twice daily until intolerable toxicity, consent withdrawal, or the investigator deemed no further benefit.

    Reporting group title
    Safety Run-In Sub-study
    Reporting group description
    Japanese participants received 200 mg intravenous tislelizumab every 3 weeks to assess preliminary safety and tolerability.

    Primary: Safety Run-in Sub-study: Number of Participants With Adverse Events (AEs)

    Close Top of page
    End point title
    Safety Run-in Sub-study: Number of Participants With Adverse Events (AEs) [1] [2]
    End point description
    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) was assessed per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03, using relevant physical examinations, electrocardiograms (ECGs), and laboratory assessments as needed. An adverse event (AE) is any unfavorable or unintended sign (e.g., abnormal lab result), symptom, or disease temporally associated with study drug use, regardless of causality. An SAE is defined as any adverse event that: Results in death Is life-threatening Requires or prolongs hospitalization Causes disability/incapacity Leads to a congenital anomaly/birth defect Is deemed medically significant by the investigator (e.g., requiring intervention to prevent severe outcomes).
    End point type
    Primary
    End point timeframe
    From the first dose to 30 days after the last dose, new anticancer therapy, or the analysis cutoff on 14 December 2023 (a maximum of 64 months)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Safety data are reported as a secondary endpoint for participants in the main study.
    End point values
    Safety Run-In Sub-study
    Number of subjects analysed
    10
    Units: Count of Participants
        TEAEs
    8
        SAEs
    1
    No statistical analyses for this end point

    Primary: Overall Survival (OS)

    Close Top of page
    End point title
    Overall Survival (OS) [3]
    End point description
    Defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using Kaplan-Meier methodology.
    End point type
    Primary
    End point timeframe
    Through the primary analysis data cut-off date of July 11th, 2022 (up to approximately 55 months)
    Notes
    [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: Months
        median (confidence interval 95%)
    15.9 (13.2 to 19.7)
    14.1 (12.6 to 17.4)
    Statistical analysis title
    Overall Survival (OS) Non-inferiority
    Comparison groups
    Arm A: Tislelizumab v Arm B: Sorafenib
    Number of subjects included in analysis
    674
    Analysis specification
    Pre-specified
    Analysis type
    non-inferiority [4]
    Method
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.85
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.712
         upper limit
    1.019
    Notes
    [4] - Overall survival (OS) was compared between the tislelizumab group (Arm A) and the sorafenib group (Arm B) by testing the null hypothesis of noninferiority: the null hypothesis assumes the hazard ratio for tislelizumab versus sorafenib is greater than or equal to 1.08, while the alternative hypothesis assumes the hazard ratio is less than 1.08. Noninferiority was declared if the upper limit of the 95.003% CI for the HR was less than 1.08.
    Statistical analysis title
    Overall Survival (OS) Superiority
    Comparison groups
    Arm A: Tislelizumab v Arm B: Sorafenib
    Number of subjects included in analysis
    674
    Analysis specification
    Pre-specified
    Analysis type
    superiority [5]
    P-value
    = 0.0398 [6]
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.85
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.712
         upper limit
    1.019
    Notes
    [5] - Superiority of tislelizumab over sorafenib was tested for OS using a stratified log-rank test in the ITT analysis set only when noninferiority was demonstrated. Superiority was declared if the one-sided pvalue crosses the boundary of 0.0223 (1-sided p-value < 0.0223) in favor of Arm A in the stratified logrank test.
    [6] - One-sided log-rank test stratified by geography (Asia vs EU/US), macrovascular invasion and/or extrahepatic spread (present vs. absent), etiology (HCV vs. Other) and ECOG (0 vs. 1).

    Secondary: Overall Response Rate (ORR) as Assessed by Blinded Independent Review Committee (BIRC)

    Close Top of page
    End point title
    Overall Response Rate (ORR) as Assessed by Blinded Independent Review Committee (BIRC) [7]
    End point description
    Defined as the percentage of participants who had partial response or complete response as determined by Blinded Independent Review Committee (BIRC) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in all randomized participants with measurable disease at baseline.
    End point type
    Secondary
    End point timeframe
    Through the primary analysis data cut-off date of July 11th, 2022 (up to approximately 55 months)
    Notes
    [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: Percentage of Participants
        number (confidence interval 95%)
    14.3 (10.8 to 18.5)
    5.4 (3.2 to 8.4)
    Statistical analysis title
    ORR by BIRC
    Statistical analysis description
    The null hypothesis assumed that ORR is equal in both groups, while the alternative hypothesis assumed ORR is higher in the tislelizumab group (Arm A).
    Comparison groups
    Arm A: Tislelizumab v Arm B: Sorafenib
    Number of subjects included in analysis
    674
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    = 0.0003 [8]
    Method
    Cochran-Mantel-Haenszel
    Confidence interval
    Notes
    [8] - The nominal P-value from the Cochran-Mantel-Haenszel chi-square test, conducted at a 0.05 significance level, was stratified by geography, macrovascular invasion/extrahepatic spread, etiology, and ECOG.

    Secondary: Overall Response Rate (ORR) as Assessed by the Investigator

    Close Top of page
    End point title
    Overall Response Rate (ORR) as Assessed by the Investigator [9]
    End point description
    Defined as the percentage of participants who had partial response or complete response as determined by investigator per RECIST v1.1 in all randomized participants with measurable disease at baseline.
    End point type
    Secondary
    End point timeframe
    Through the study completion data cut-off date of December 14th, 2023 (up to approximately 65 months)
    Notes
    [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: percentage of participants
        number (confidence interval 95%)
    15.5 (11.8 to 19.8)
    5.7 (3.5 to 8.8)
    Statistical analysis title
    ORR by Investigator
    Comparison groups
    Arm A: Tislelizumab v Arm B: Sorafenib
    Number of subjects included in analysis
    674
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    < 0.0001 [10]
    Method
    Cochran-Mantel-Haenszel
    Confidence interval
    Notes
    [10] - The nominal P-value from the Cochran-Mantel-Haenszel chi-square test, conducted at a 0.05 significance level, was stratified by geography, macrovascular invasion/extrahepatic spread, etiology, and ECOG.

    Secondary: Progression Free Survival (PFS) as Assessed by BIRC

    Close Top of page
    End point title
    Progression Free Survival (PFS) as Assessed by BIRC [11]
    End point description
    Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the BIRC per RECIST v1.1. Kaplan-Meier methodology was used to estimate the median PFS.
    End point type
    Secondary
    End point timeframe
    Through the primary analysis data cut-off date of July 11th, 2022 (up to approximately 55 months)
    Notes
    [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: Months
        median (confidence interval 95%)
    2.1 (2.1 to 3.5)
    3.4 (2.2 to 4.1)
    Statistical analysis title
    PFS by BIRC
    Comparison groups
    Arm A: Tislelizumab v Arm B: Sorafenib
    Number of subjects included in analysis
    674
    Analysis specification
    Pre-specified
    Analysis type
    other [12]
    P-value
    = 0.1364 [13]
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.11
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.92
         upper limit
    1.33
    Notes
    [12] - The hazard ratio was derived from a Cox regression model with treatment as a covariate and stratified by geography (Asia vs. EU/US), macrovascular invasion/extrahepatic spread (present vs. absent), etiology (HCV vs. other), and ECOG score (0 vs. 1).
    [13] - One sided Log-Rank Test stratified by geography (Asia vs EU/US), macrovascular invasion and/or extrahepatic spread (present vs. absent), etiology (HCV vs. Other) and ECOG (0 vs. 1).

    Secondary: Progression Free Survival (PFS) as Assessed by the Investigator

    Close Top of page
    End point title
    Progression Free Survival (PFS) as Assessed by the Investigator [14]
    End point description
    Defined as the time from randomization to the first objectively documented disease progression, or death from any cause, whichever occurred first, as assessed by the investigator per RECIST v1.1. Kaplan-Meier methodology was used to estimate the median PFS.
    End point type
    Secondary
    End point timeframe
    Through the study completion data cut-off date of December 14th, 2023 (up to approximately 65 months)
    Notes
    [14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: Months
        median (confidence interval 95%)
    2.1 (2.1 to 2.3)
    4.0 (2.7 to 4.1)
    Statistical analysis title
    PFS by Investigator
    Statistical analysis description
    The hazard ratio was derived from a Cox regression model with treatment as a covariate and stratified by geography (Asia vs. EU/US), macrovascular invasion/extrahepatic spread (present vs. absent), etiology (HCV vs. other), and ECOG score (0 vs. 1).
    Comparison groups
    Arm A: Tislelizumab v Arm B: Sorafenib
    Number of subjects included in analysis
    674
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    = 0.2622 [15]
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.06
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.9
         upper limit
    1.26
    Notes
    [15] - One sided Log-Rank Test stratified by geography (Asia vs EU/US), macrovascular invasion and/or extrahepatic spread (present vs. absent), etiology (HCV vs. Other) and ECOG (0 vs. 1).

    Secondary: Duration of Response (DOR) as Assessed by BIRC

    Close Top of page
    End point title
    Duration of Response (DOR) as Assessed by BIRC [16]
    End point description
    Defined as the time from the first occurrence of a documented objective response until the first documentation of progression or death from any cause, whichever comes first, as determined by the BIRC per RECIST v1.1. Median DOR was estimated using Kaplan-Meier methodology. ITT Analysis Set. Only participants with best overall response of complete response or partial response confirmed per RECIST v1.1 were included in the analysis, and percentages were based on the number of responders.
    End point type
    Secondary
    End point timeframe
    Through the primary analysis data cut-off date of July 11th, 2022 (up to approximately 55 months)
    Notes
    [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    49
    18
    Units: Months
        median (confidence interval 95%)
    36.1 (16.8 to 9999)
    11.0 (6.2 to 14.7)
    No statistical analyses for this end point

    Secondary: Duration of Response (DOR) as Assessed by the Investigator

    Close Top of page
    End point title
    Duration of Response (DOR) as Assessed by the Investigator [17]
    End point description
    Defined as the time from the first occurrence of a documented objective response until the first documentation of progression or death from any cause, whichever comes first, as assessed by the investigator per RECIST v1.1. Median DOR was estimated using Kaplan-Meier methodology. ITT Analysis Set. Only participants with best overall response of complete response or partial response confirmed per RECIST v1.1 were included in the analysis, and percentages were based on the number of responders.
    End point type
    Secondary
    End point timeframe
    Through the study completion data cut-off date of December 14th, 2023 (up to approximately 65 months)
    Notes
    [17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    53
    19
    Units: Months
        median (confidence interval 95%)
    25.2 (18.1 to 46.8)
    13.8 (6.2 to 20.3)
    No statistical analyses for this end point

    Secondary: Time to Progression (TTP) as Assessed by BIRC

    Close Top of page
    End point title
    Time to Progression (TTP) as Assessed by BIRC [18]
    End point description
    Defined as the time from the date of randomization to the date of the first objectively documented tumor progression as assessed by the BIRC per RECIST v1.1.
    End point type
    Secondary
    End point timeframe
    Through the primary analysis data cut-off date of July 11th, 2022 (up to approximately 55 months)
    Notes
    [18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: Months
        median (confidence interval 95%)
    2.2 (2.1 to 3.6)
    4.1 (2.2 to 4.1)
    Statistical analysis title
    TPP by BIRC
    Comparison groups
    Arm A: Tislelizumab v Arm B: Sorafenib
    Number of subjects included in analysis
    674
    Analysis specification
    Pre-specified
    Analysis type
    other [19]
    P-value
    = 0.0859 [20]
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.14
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.94
         upper limit
    1.38
    Notes
    [19] - The hazard ratio was derived from a Cox regression model with treatment as a covariate and stratified by geography (Asia vs. EU/US), macrovascular invasion/extrahepatic spread (present vs. absent), etiology (HCV vs. other), and ECOG score (0 vs. 1).
    [20] - One sided Log-Rank Test stratified by geography (Asia vs EU/US), macrovascular invasion and/or extrahepatic spread (present vs. absent), etiology (HCV vs. Other) and ECOG (0 vs. 1).

    Secondary: Time to Progression (TTP) as Assessed by the Investigator

    Close Top of page
    End point title
    Time to Progression (TTP) as Assessed by the Investigator [21]
    End point description
    Defined as the time from the date of randomization to the date of the first objectively documented tumor progression as assessed by the investigator per RECIST v1.1.
    End point type
    Secondary
    End point timeframe
    Through the study completion data cut-off date of December 14th, 2023 (up to approximately 65 months)
    Notes
    [21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: Months
        median (confidence interval 95%)
    2.1 (2.1 to 3.3)
    4.1 (3.4 to 4.2)
    Statistical analysis title
    TPP by Investigator
    Comparison groups
    Arm A: Tislelizumab v Arm B: Sorafenib
    Number of subjects included in analysis
    674
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    = 0.1182 [22]
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.12
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.94
         upper limit
    1.34
    Notes
    [22] - One sided Log-Rank Test stratified by geography (Asia vs EU/US), macrovascular invasion and/or extrahepatic spread (present vs. absent), etiology (HCV vs. Other) and ECOG (0 vs. 1).

    Secondary: Disease Control Rate (DCR) as Assessed by the Investigator

    Close Top of page
    End point title
    Disease Control Rate (DCR) as Assessed by the Investigator [23]
    End point description
    Defined as the percentage of participants whose best overall response (BOR) is complete response, partial response, or stable disease per RECIST v1.1.
    End point type
    Secondary
    End point timeframe
    Through the study completion data cut-off date of December 14th, 2023 (up to approximately 65 months)
    Notes
    [23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: Percentage of Participants
        number (not applicable)
    44.2
    52.4
    No statistical analyses for this end point

    Secondary: Clinical Benefit Rate (CBR) as Assessed by BIRC

    Close Top of page
    End point title
    Clinical Benefit Rate (CBR) as Assessed by BIRC [24]
    End point description
    Defined as the percentage of participants whose best overall response (BOR) is complete response, partial response, or stable disease greater than or equal to 24 weeks in duration, per RECIST v1.1.
    End point type
    Secondary
    End point timeframe
    Through the primary analysis data cut-off date of July 11th, 2022 (up to approximately 55 months)
    Notes
    [24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: Percentage of Participants
        number (not applicable)
    25.4
    24.4
    No statistical analyses for this end point

    Secondary: Clinical Benefit Rate (CBR) as Assessed by the Investigator

    Close Top of page
    End point title
    Clinical Benefit Rate (CBR) as Assessed by the Investigator [25]
    End point description
    Defined as the percentage of participants whose best overall response (BOR) is complete response, partial response, or stable disease greater than or equal to 24 weeks in duration, per RECIST v1.1.
    End point type
    Secondary
    End point timeframe
    Through the study completion data cut-off date of December 14th, 2023 (up to approximately 65 months)
    Notes
    [25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: Percentage of Participants
        number (not applicable)
    25.7
    28.9
    No statistical analyses for this end point

    Secondary: Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Hepatocellular Carcinoma 18 Questions (EORTC QLQ HCC 18) Index Score

    Close Top of page
    End point title
    Change From Baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Hepatocellular Carcinoma 18 Questions (EORTC QLQ HCC 18) Index Score [26]
    End point description
    The EORTC QLQ-HCC18 is a questionnaire specifically designed to assess health-related quality of life in participants with hepatocellular carcinoma. It includes six symptom scales measuring Fatigue (3 items), Jaundice (2 items), Body Image (2 items), Nutrition (5 items), Pain (2 items), Fever (2 items) and two single items measuring Sex Life and Abdominal Swelling. Participants respond on a scale from 1 = "Not at all" to 4 = "Very Much. Raw scores are transformed into a 0 to 100 scale using linear transformation. The HCC18 Index score is calculated from each of the 6 symptom scales and the 2 single items, and ranges from 0 to 100. Higher scores indicate greater symptom burden or worse quality of life.
    End point type
    Secondary
    End point timeframe
    Baseline to Cycles 4 and 6 (Each cycle was 21 days)
    Notes
    [26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342 [27]
    332 [28]
    Units: Score on a Scale
    arithmetic mean (standard deviation)
        Cycle 4
    0.5 ( 8.12 )
    3.2 ( 9.25 )
        Cycle 6
    1.2 ( 9.88 )
    3.6 ( 10.38 )
    Notes
    [27] - 212 participants were analyzed in Cycle 4 and 160 participants in Cycle 6
    [28] - 171 participants were analyzed in Cycle 4 and 134 participants in Cycle 6
    No statistical analyses for this end point

    Secondary: Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Score

    Close Top of page
    End point title
    Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Score [29]
    End point description
    The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes. Only participants with data at both baseline and corresponding post-baseline visit are included in the analysis at each time point.
    End point type
    Secondary
    End point timeframe
    Baseline to Cycles 4 and 6 (Each cycle was 21 days)
    Notes
    [29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342 [30]
    332 [31]
    Units: Score on a scale
    arithmetic mean (standard deviation)
        Cycle 4
    0.5 ( 17.20 )
    -3.3 ( 19.25 )
        Cycle 6
    0.4 ( 17.99 )
    -3.4 ( 16.58 )
    Notes
    [30] - 213 participants were analyzed in Cycle 4 and 161 participants in Cycle 6
    [31] - 171 participants were analyzed in Cycle 4 and 133 participants in Cycle 6
    No statistical analyses for this end point

    Secondary: Change From Baseline in the European Quality of Life 5 Dimensions, 5-level (EQ5D-5L) Visual Analogue Scale (VAS)

    Close Top of page
    End point title
    Change From Baseline in the European Quality of Life 5 Dimensions, 5-level (EQ5D-5L) Visual Analogue Scale (VAS) [32]
    End point description
    The EQ-5D-5L comprises a descriptive module and a Visual Analogue scale (VAS). The EQ VAS measures respondent's self-rated health status on a 0 to 100 scale, with 100 = 'the best health you can imagine' and 0 = 'the worst health you can imagine'. Higher scores on VAS indicate higher health status. Only participants with data at both baseline and corresponding post-baseline visit are included in the analysis at each time point.
    End point type
    Secondary
    End point timeframe
    Baseline to Cycles 4 and 6 (Each cycle was 21 days)
    Notes
    [32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342 [33]
    332 [34]
    Units: Score on a Scale
    arithmetic mean (standard deviation)
        Cycle 4
    -0.4 ( 14.52 )
    -4.3 ( 12.92 )
        Cycle 6
    -0.2 ( 17.03 )
    -5.4 ( 13.09 )
    Notes
    [33] - 213 participants were analyzed in Cycle 4 and 161 were analyzed in Cycle 6.
    [34] - 170 participants were analyzed in Cycle 4 and 132 were analyzed in Cycle 6.
    No statistical analyses for this end point

    Secondary: Number of Participants With Adverse Events

    Close Top of page
    End point title
    Number of Participants With Adverse Events [35]
    End point description
    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. The Safety Analysis Set includes all patients randomized and received at least one dose of any study drug.
    End point type
    Secondary
    End point timeframe
    From the first dose to 30 days after the last dose, new anticancer therapy, or the study completion analysis cutoff on December 14th, 2023 (a maximum of 61 months for participants in Arm A and 63 months for participants in Arm B).
    Notes
    [35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was assessed as a primary endpoint in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    338
    324
    Units: Participants
        TEAEs
    325
    324
        SAEs
    104
    91
    No statistical analyses for this end point

    Secondary: Disease Control Rate (DCR) as Assessed by BIRC

    Close Top of page
    End point title
    Disease Control Rate (DCR) as Assessed by BIRC [36]
    End point description
    Defined as the percentage of participants whose best overall response (BOR) is complete response, partial response, or stable disease per RECIST v1.1.
    End point type
    Secondary
    End point timeframe
    Through the primary analysis data cut-off date of July 11th, 2022 (up to approximately 55 months)
    Notes
    [36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This endpoint was not assessed in the safety run-in sub-study.
    End point values
    Arm A: Tislelizumab Arm B: Sorafenib
    Number of subjects analysed
    342
    332
    Units: Percentage of Participants
        number (not applicable)
    44.2
    50.3
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose to 30 days after last dose, new anticancer therapy, or the study completion analysis cutoff on December 14th, 2023 (a maximum of 61 months for participants in Arm A, 63 months in Arm B, and 64 months in the Safety Run-in sub-study).
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    25.0
    Reporting groups
    Reporting group title
    Arm A: Tislelizumab
    Reporting group description
    Participants received 200 mg of intravenous tislelizumab every 3 weeks until intolerable toxicity, withdrawal of consent, or the investigator determined no further benefit from the therapy.

    Reporting group title
    Arm B: Sorafenib
    Reporting group description
    Participants received 400 mg of oral sorafenib twice daily until intolerable toxicity, consent withdrawal, or the investigator deemed no further benefit.

    Reporting group title
    Safety Run-In Sub-study
    Reporting group description
    Japanese participants received 200 mg intravenous tislelizumab every 3 weeks to assess preliminary safety and tolerability.

    Serious adverse events
    Arm A: Tislelizumab Arm B: Sorafenib Safety Run-In Sub-study
    Total subjects affected by serious adverse events
         subjects affected / exposed
    104 / 338 (30.77%)
    91 / 324 (28.09%)
    1 / 10 (10.00%)
         number of deaths (all causes)
    258
    273
    7
         number of deaths resulting from adverse events
    16
    17
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Cancer pain
         subjects affected / exposed
    1 / 338 (0.30%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Colon cancer
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intraductal papillary mucinous neoplasm
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Liver carcinoma ruptured
         subjects affected / exposed
    2 / 338 (0.59%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    1 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    1 / 1
    0 / 0
    Oesophageal adenocarcinoma
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Squamous cell carcinoma of skin
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Tumour pain
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Tumour rupture
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    0 / 338 (0.00%)
    3 / 324 (0.93%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lipoma
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Circulatory collapse
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    Hypotension
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    Peripheral arterial occlusive disease
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Peripheral vascular disorder
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Shock haemorrhagic
         subjects affected / exposed
    0 / 338 (0.00%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
    Surgical and medical procedures
    Radiotherapy
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Death
         subjects affected / exposed
    1 / 338 (0.30%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    Fatigue
         subjects affected / exposed
    1 / 338 (0.30%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gait disturbance
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    1 / 338 (0.30%)
    4 / 324 (1.23%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 3
    0 / 0
    Malaise
         subjects affected / exposed
    0 / 338 (0.00%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    1 / 338 (0.30%)
    3 / 324 (0.93%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 3
    0 / 0
    Non-cardiac chest pain
         subjects affected / exposed
    1 / 338 (0.30%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Oedema peripheral
         subjects affected / exposed
    0 / 338 (0.00%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    3 / 338 (0.89%)
    5 / 324 (1.54%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    3 / 5
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Pelvic fluid collection
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    0 / 338 (0.00%)
    4 / 324 (1.23%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    Haemoptysis
         subjects affected / exposed
    1 / 338 (0.30%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatopulmonary syndrome
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    Hydrothorax
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Immune-mediated lung disease
         subjects affected / exposed
    2 / 338 (0.59%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pulmonary alveolar haemorrhage
         subjects affected / exposed
    0 / 338 (0.00%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    Pulmonary mass
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    0 / 338 (0.00%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    5 / 338 (1.48%)
    4 / 324 (1.23%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    4 / 5
    3 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Blood bilirubin increased
         subjects affected / exposed
    0 / 338 (0.00%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    2 / 338 (0.59%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    2 / 338 (0.59%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatic enzyme abnormal
         subjects affected / exposed
    2 / 338 (0.59%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Transaminases increased
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Weight decreased
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Ankle fracture
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Craniocerebral injury
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Extradural haematoma
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Femur fracture
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Fracture
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatic rupture
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Humerus fracture
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Limb injury
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Radiation oesophagitis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Aspartate aminotransferase increased
         subjects affected / exposed
    6 / 338 (1.78%)
    5 / 324 (1.54%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    5 / 7
    5 / 5
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac failure
         subjects affected / exposed
    0 / 338 (0.00%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    Microvascular coronary artery disease
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pericarditis
         subjects affected / exposed
    1 / 338 (0.30%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ventricular fibrillation
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ventricular tachycardia
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    Nervous system disorders
    Cerebral haemorrhage
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Dizziness
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Encephalopathy
         subjects affected / exposed
    1 / 338 (0.30%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hemiparesis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hemiplegia
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Hepatic encephalopathy
         subjects affected / exposed
    1 / 338 (0.30%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hypoaesthesia
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hypoxic-ischaemic encephalopathy
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Loss of consciousness
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Seizure
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Subarachnoid haemorrhage
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vocal cord paralysis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Cold type haemolytic anaemia
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hypersplenism
         subjects affected / exposed
    1 / 338 (0.30%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lymphopenia
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Cataract
         subjects affected / exposed
    2 / 338 (0.59%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    2 / 338 (0.59%)
    4 / 324 (1.23%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    1 / 5
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    2 / 338 (0.59%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Anorectal varices
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Ascites
         subjects affected / exposed
    4 / 338 (1.18%)
    4 / 324 (1.23%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    1 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Chronic gastritis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Duodenal ulcer
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastric haemorrhage
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    2 / 338 (0.59%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Haemoperitoneum
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Immune-mediated enterocolitis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    3 / 338 (0.89%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Intra-abdominal fluid collection
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Oesophageal varices haemorrhage
         subjects affected / exposed
    3 / 338 (0.89%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Subileus
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed
    4 / 338 (1.18%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Varices oesophageal
         subjects affected / exposed
    2 / 338 (0.59%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Acute hepatic failure
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Biliary obstruction
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Drug-induced liver injury
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatic cirrhosis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatic failure
         subjects affected / exposed
    4 / 338 (1.18%)
    3 / 324 (0.93%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    3 / 4
    2 / 3
    0 / 0
         deaths causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    Hepatic function abnormal
         subjects affected / exposed
    2 / 338 (0.59%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatic haemorrhage
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hepatitis
         subjects affected / exposed
    2 / 338 (0.59%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hyperbilirubinaemia
         subjects affected / exposed
    1 / 338 (0.30%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Immune-mediated hepatitis
         subjects affected / exposed
    3 / 338 (0.89%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Jaundice
         subjects affected / exposed
    3 / 338 (0.89%)
    5 / 324 (1.54%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    1 / 5
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Jaundice cholestatic
         subjects affected / exposed
    2 / 338 (0.59%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Jaundice hepatocellular
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Portal vein thrombosis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Acute generalised exanthematous pustulosis
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Immune-mediated dermatitis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rash
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rash maculo-papular
         subjects affected / exposed
    0 / 338 (0.00%)
    2 / 324 (0.62%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    3 / 338 (0.89%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Proteinuria
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Endocrine disorders
    Hypothyroidism
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    2 / 338 (0.59%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Muscular weakness
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Osteolysis
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pain in extremity
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Psoriatic arthropathy
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Rhabdomyolysis
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Appendicitis
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Bacteraemia
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Biliary tract infection
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Colonic abscess
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Lung abscess
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    5 / 338 (1.48%)
    3 / 324 (0.93%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    1 / 5
    0 / 3
    1 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    Pulmonary sepsis
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    Pulmonary tuberculosis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 338 (0.30%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Tuberculosis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Varicella
         subjects affected / exposed
    0 / 338 (0.00%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Diabetes mellitus inadequate control
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hyperamylasaemia
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed
    2 / 338 (0.59%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    3 / 338 (0.89%)
    0 / 324 (0.00%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Hypophosphataemia
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    0 / 10 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 3%
    Non-serious adverse events
    Arm A: Tislelizumab Arm B: Sorafenib Safety Run-In Sub-study
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    313 / 338 (92.60%)
    318 / 324 (98.15%)
    8 / 10 (80.00%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    23 / 338 (6.80%)
    90 / 324 (27.78%)
    1 / 10 (10.00%)
         occurrences all number
    27
    126
    1
    Hypotension
         subjects affected / exposed
    5 / 338 (1.48%)
    2 / 324 (0.62%)
    1 / 10 (10.00%)
         occurrences all number
    5
    2
    3
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    34 / 338 (10.06%)
    26 / 324 (8.02%)
    0 / 10 (0.00%)
         occurrences all number
    40
    34
    0
    Fatigue
         subjects affected / exposed
    36 / 338 (10.65%)
    37 / 324 (11.42%)
    3 / 10 (30.00%)
         occurrences all number
    40
    48
    3
    Infusion site extravasation
         subjects affected / exposed
    0 / 338 (0.00%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    0
    1
    Malaise
         subjects affected / exposed
    13 / 338 (3.85%)
    14 / 324 (4.32%)
    0 / 10 (0.00%)
         occurrences all number
    13
    15
    0
    Oedema peripheral
         subjects affected / exposed
    21 / 338 (6.21%)
    16 / 324 (4.94%)
    2 / 10 (20.00%)
         occurrences all number
    25
    16
    2
    Pyrexia
         subjects affected / exposed
    56 / 338 (16.57%)
    56 / 324 (17.28%)
    4 / 10 (40.00%)
         occurrences all number
    77
    75
    4
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    38 / 338 (11.24%)
    25 / 324 (7.72%)
    1 / 10 (10.00%)
         occurrences all number
    44
    27
    1
    Dysphonia
         subjects affected / exposed
    1 / 338 (0.30%)
    28 / 324 (8.64%)
    0 / 10 (0.00%)
         occurrences all number
    1
    30
    0
    Dyspnoea
         subjects affected / exposed
    12 / 338 (3.55%)
    8 / 324 (2.47%)
    0 / 10 (0.00%)
         occurrences all number
    13
    8
    0
    Epistaxis
         subjects affected / exposed
    5 / 338 (1.48%)
    8 / 324 (2.47%)
    1 / 10 (10.00%)
         occurrences all number
    5
    10
    1
    Oropharyngeal pain
         subjects affected / exposed
    5 / 338 (1.48%)
    12 / 324 (3.70%)
    1 / 10 (10.00%)
         occurrences all number
    6
    15
    1
    Pulmonary artery thrombosis
         subjects affected / exposed
    0 / 338 (0.00%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    0
    1
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    19 / 338 (5.62%)
    17 / 324 (5.25%)
    1 / 10 (10.00%)
         occurrences all number
    20
    21
    1
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    93 / 338 (27.51%)
    111 / 324 (34.26%)
    0 / 10 (0.00%)
         occurrences all number
    133
    168
    0
    Amylase increased
         subjects affected / exposed
    0 / 338 (0.00%)
    4 / 324 (1.23%)
    1 / 10 (10.00%)
         occurrences all number
    0
    5
    1
    Aspartate aminotransferase increased
         subjects affected / exposed
    124 / 338 (36.69%)
    135 / 324 (41.67%)
    1 / 10 (10.00%)
         occurrences all number
    179
    213
    1
    Bilirubin conjugated increased
         subjects affected / exposed
    28 / 338 (8.28%)
    33 / 324 (10.19%)
    0 / 10 (0.00%)
         occurrences all number
    40
    56
    0
    Blood alkaline phosphatase increased
         subjects affected / exposed
    42 / 338 (12.43%)
    37 / 324 (11.42%)
    0 / 10 (0.00%)
         occurrences all number
    69
    52
    0
    Blood bilirubin increased
         subjects affected / exposed
    74 / 338 (21.89%)
    101 / 324 (31.17%)
    1 / 10 (10.00%)
         occurrences all number
    143
    167
    1
    Blood bilirubin unconjugated increased
         subjects affected / exposed
    12 / 338 (3.55%)
    13 / 324 (4.01%)
    0 / 10 (0.00%)
         occurrences all number
    19
    25
    0
    Blood creatine phosphokinase MB increased
         subjects affected / exposed
    17 / 338 (5.03%)
    13 / 324 (4.01%)
    0 / 10 (0.00%)
         occurrences all number
    20
    17
    0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    20 / 338 (5.92%)
    13 / 324 (4.01%)
    0 / 10 (0.00%)
         occurrences all number
    27
    26
    0
    Blood creatinine increased
         subjects affected / exposed
    9 / 338 (2.66%)
    3 / 324 (0.93%)
    1 / 10 (10.00%)
         occurrences all number
    17
    5
    1
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    24 / 338 (7.10%)
    28 / 324 (8.64%)
    0 / 10 (0.00%)
         occurrences all number
    33
    55
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    43 / 338 (12.72%)
    42 / 324 (12.96%)
    0 / 10 (0.00%)
         occurrences all number
    61
    51
    0
    Hepatitis C RNA increased
         subjects affected / exposed
    0 / 338 (0.00%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    0
    1
    Neutrophil count decreased
         subjects affected / exposed
    30 / 338 (8.88%)
    29 / 324 (8.95%)
    1 / 10 (10.00%)
         occurrences all number
    65
    59
    1
    Platelet count decreased
         subjects affected / exposed
    50 / 338 (14.79%)
    69 / 324 (21.30%)
    0 / 10 (0.00%)
         occurrences all number
    81
    106
    0
    Weight decreased
         subjects affected / exposed
    35 / 338 (10.36%)
    63 / 324 (19.44%)
    0 / 10 (0.00%)
         occurrences all number
    40
    72
    0
    White blood cell count decreased
         subjects affected / exposed
    32 / 338 (9.47%)
    31 / 324 (9.57%)
    0 / 10 (0.00%)
         occurrences all number
    63
    69
    0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    0 / 338 (0.00%)
    2 / 324 (0.62%)
    1 / 10 (10.00%)
         occurrences all number
    0
    2
    1
    Post procedural fever
         subjects affected / exposed
    0 / 338 (0.00%)
    1 / 324 (0.31%)
    1 / 10 (10.00%)
         occurrences all number
    0
    1
    1
    Procedural pain
         subjects affected / exposed
    1 / 338 (0.30%)
    1 / 324 (0.31%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    1
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    2 / 338 (0.59%)
    4 / 324 (1.23%)
    1 / 10 (10.00%)
         occurrences all number
    2
    4
    2
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    12 / 338 (3.55%)
    8 / 324 (2.47%)
    1 / 10 (10.00%)
         occurrences all number
    16
    10
    1
    Dysgeusia
         subjects affected / exposed
    5 / 338 (1.48%)
    2 / 324 (0.62%)
    1 / 10 (10.00%)
         occurrences all number
    6
    2
    1
    Headache
         subjects affected / exposed
    16 / 338 (4.73%)
    17 / 324 (5.25%)
    0 / 10 (0.00%)
         occurrences all number
    19
    20
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    41 / 338 (12.13%)
    32 / 324 (9.88%)
    3 / 10 (30.00%)
         occurrences all number
    73
    47
    3
    Leukopenia
         subjects affected / exposed
    14 / 338 (4.14%)
    18 / 324 (5.56%)
    0 / 10 (0.00%)
         occurrences all number
    29
    26
    0
    Neutropenia
         subjects affected / exposed
    3 / 338 (0.89%)
    13 / 324 (4.01%)
    0 / 10 (0.00%)
         occurrences all number
    21
    16
    0
    Thrombocytopenia
         subjects affected / exposed
    15 / 338 (4.44%)
    31 / 324 (9.57%)
    0 / 10 (0.00%)
         occurrences all number
    24
    47
    0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    5 / 338 (1.48%)
    1 / 324 (0.31%)
    1 / 10 (10.00%)
         occurrences all number
    5
    1
    2
    Gastrointestinal disorders
    Abdominal distension
         subjects affected / exposed
    32 / 338 (9.47%)
    20 / 324 (6.17%)
    1 / 10 (10.00%)
         occurrences all number
    36
    25
    1
    Abdominal pain
         subjects affected / exposed
    38 / 338 (11.24%)
    40 / 324 (12.35%)
    0 / 10 (0.00%)
         occurrences all number
    47
    51
    0
    Abdominal pain upper
         subjects affected / exposed
    18 / 338 (5.33%)
    32 / 324 (9.88%)
    1 / 10 (10.00%)
         occurrences all number
    20
    40
    1
    Ascites
         subjects affected / exposed
    14 / 338 (4.14%)
    8 / 324 (2.47%)
    0 / 10 (0.00%)
         occurrences all number
    14
    8
    0
    Constipation
         subjects affected / exposed
    28 / 338 (8.28%)
    28 / 324 (8.64%)
    0 / 10 (0.00%)
         occurrences all number
    35
    36
    0
    Diarrhoea
         subjects affected / exposed
    38 / 338 (11.24%)
    142 / 324 (43.83%)
    1 / 10 (10.00%)
         occurrences all number
    52
    379
    1
    Dry mouth
         subjects affected / exposed
    11 / 338 (3.25%)
    10 / 324 (3.09%)
    0 / 10 (0.00%)
         occurrences all number
    13
    11
    0
    Dyspepsia
         subjects affected / exposed
    14 / 338 (4.14%)
    10 / 324 (3.09%)
    1 / 10 (10.00%)
         occurrences all number
    15
    18
    2
    Nausea
         subjects affected / exposed
    27 / 338 (7.99%)
    33 / 324 (10.19%)
    0 / 10 (0.00%)
         occurrences all number
    29
    34
    0
    Stomatitis
         subjects affected / exposed
    9 / 338 (2.66%)
    17 / 324 (5.25%)
    1 / 10 (10.00%)
         occurrences all number
    10
    23
    2
    Vomiting
         subjects affected / exposed
    25 / 338 (7.40%)
    16 / 324 (4.94%)
    1 / 10 (10.00%)
         occurrences all number
    31
    25
    1
    Hepatobiliary disorders
    Hepatic pain
         subjects affected / exposed
    13 / 338 (3.85%)
    12 / 324 (3.70%)
    0 / 10 (0.00%)
         occurrences all number
    16
    14
    0
    Hyperbilirubinaemia
         subjects affected / exposed
    14 / 338 (4.14%)
    16 / 324 (4.94%)
    0 / 10 (0.00%)
         occurrences all number
    25
    30
    0
    Portal vein thrombosis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    1
    0
    1
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    2 / 338 (0.59%)
    75 / 324 (23.15%)
    0 / 10 (0.00%)
         occurrences all number
    2
    76
    0
    Dermatitis
         subjects affected / exposed
    5 / 338 (1.48%)
    1 / 324 (0.31%)
    1 / 10 (10.00%)
         occurrences all number
    5
    1
    1
    Dermatitis psoriasiform
         subjects affected / exposed
    0 / 338 (0.00%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    0
    1
    Dry skin
         subjects affected / exposed
    12 / 338 (3.55%)
    6 / 324 (1.85%)
    1 / 10 (10.00%)
         occurrences all number
    13
    7
    1
    Erythema
         subjects affected / exposed
    3 / 338 (0.89%)
    11 / 324 (3.40%)
    0 / 10 (0.00%)
         occurrences all number
    3
    11
    0
    Neurodermatitis
         subjects affected / exposed
    1 / 338 (0.30%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    4
    0
    1
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    1 / 338 (0.30%)
    203 / 324 (62.65%)
    1 / 10 (10.00%)
         occurrences all number
    1
    231
    1
    Pruritus
         subjects affected / exposed
    48 / 338 (14.20%)
    25 / 324 (7.72%)
    0 / 10 (0.00%)
         occurrences all number
    58
    28
    0
    Rash
         subjects affected / exposed
    40 / 338 (11.83%)
    56 / 324 (17.28%)
    3 / 10 (30.00%)
         occurrences all number
    50
    65
    4
    Rash maculo-papular
         subjects affected / exposed
    4 / 338 (1.18%)
    15 / 324 (4.63%)
    0 / 10 (0.00%)
         occurrences all number
    4
    17
    0
    Skin disorder
         subjects affected / exposed
    0 / 338 (0.00%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    0
    1
    Urticaria
         subjects affected / exposed
    2 / 338 (0.59%)
    1 / 324 (0.31%)
    1 / 10 (10.00%)
         occurrences all number
    2
    2
    1
    Renal and urinary disorders
    Proteinuria
         subjects affected / exposed
    11 / 338 (3.25%)
    12 / 324 (3.70%)
    0 / 10 (0.00%)
         occurrences all number
    15
    12
    0
    Renal impairment
         subjects affected / exposed
    1 / 338 (0.30%)
    1 / 324 (0.31%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    1
    Endocrine disorders
    Hyperthyroidism
         subjects affected / exposed
    15 / 338 (4.44%)
    4 / 324 (1.23%)
    0 / 10 (0.00%)
         occurrences all number
    15
    47
    0
    Hypothyroidism
         subjects affected / exposed
    29 / 338 (8.58%)
    12 / 324 (3.70%)
    0 / 10 (0.00%)
         occurrences all number
    33
    12
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    40 / 338 (11.83%)
    22 / 324 (6.79%)
    0 / 10 (0.00%)
         occurrences all number
    54
    30
    0
    Back pain
         subjects affected / exposed
    29 / 338 (8.58%)
    20 / 324 (6.17%)
    1 / 10 (10.00%)
         occurrences all number
    32
    24
    1
    Muscle spasms
         subjects affected / exposed
    5 / 338 (1.48%)
    12 / 324 (3.70%)
    0 / 10 (0.00%)
         occurrences all number
    6
    16
    0
    Myalgia
         subjects affected / exposed
    5 / 338 (1.48%)
    11 / 324 (3.40%)
    0 / 10 (0.00%)
         occurrences all number
    5
    17
    0
    Pain in extremity
         subjects affected / exposed
    11 / 338 (3.25%)
    12 / 324 (3.70%)
    0 / 10 (0.00%)
         occurrences all number
    11
    18
    0
    Infections and infestations
    Folliculitis
         subjects affected / exposed
    0 / 338 (0.00%)
    2 / 324 (0.62%)
    1 / 10 (10.00%)
         occurrences all number
    0
    2
    1
    Gastroenteritis
         subjects affected / exposed
    1 / 338 (0.30%)
    1 / 324 (0.31%)
    1 / 10 (10.00%)
         occurrences all number
    1
    1
    1
    Herpes zoster
         subjects affected / exposed
    2 / 338 (0.59%)
    1 / 324 (0.31%)
    1 / 10 (10.00%)
         occurrences all number
    2
    1
    1
    Influenza
         subjects affected / exposed
    5 / 338 (1.48%)
    2 / 324 (0.62%)
    1 / 10 (10.00%)
         occurrences all number
    5
    2
    1
    Nasopharyngitis
         subjects affected / exposed
    11 / 338 (3.25%)
    11 / 324 (3.40%)
    2 / 10 (20.00%)
         occurrences all number
    13
    13
    2
    Oral candidiasis
         subjects affected / exposed
    0 / 338 (0.00%)
    4 / 324 (1.23%)
    1 / 10 (10.00%)
         occurrences all number
    0
    4
    1
    Pyelonephritis
         subjects affected / exposed
    0 / 338 (0.00%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    0
    0
    1
    Upper respiratory tract infection
         subjects affected / exposed
    30 / 338 (8.88%)
    13 / 324 (4.01%)
    0 / 10 (0.00%)
         occurrences all number
    40
    15
    0
    Urinary tract infection
         subjects affected / exposed
    12 / 338 (3.55%)
    12 / 324 (3.70%)
    1 / 10 (10.00%)
         occurrences all number
    13
    15
    2
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    45 / 338 (13.31%)
    57 / 324 (17.59%)
    3 / 10 (30.00%)
         occurrences all number
    53
    60
    3
    Diabetes mellitus
         subjects affected / exposed
    2 / 338 (0.59%)
    0 / 324 (0.00%)
    1 / 10 (10.00%)
         occurrences all number
    2
    0
    1
    Hyperglycaemia
         subjects affected / exposed
    19 / 338 (5.62%)
    18 / 324 (5.56%)
    0 / 10 (0.00%)
         occurrences all number
    54
    24
    0
    Hypoalbuminaemia
         subjects affected / exposed
    45 / 338 (13.31%)
    32 / 324 (9.88%)
    0 / 10 (0.00%)
         occurrences all number
    81
    44
    0
    Hypocalcaemia
         subjects affected / exposed
    7 / 338 (2.07%)
    15 / 324 (4.63%)
    0 / 10 (0.00%)
         occurrences all number
    9
    22
    0
    Hypokalaemia
         subjects affected / exposed
    21 / 338 (6.21%)
    34 / 324 (10.49%)
    1 / 10 (10.00%)
         occurrences all number
    43
    63
    1
    Hypomagnesaemia
         subjects affected / exposed
    9 / 338 (2.66%)
    12 / 324 (3.70%)
    0 / 10 (0.00%)
         occurrences all number
    24
    18
    0
    Hyponatraemia
         subjects affected / exposed
    20 / 338 (5.92%)
    28 / 324 (8.64%)
    0 / 10 (0.00%)
         occurrences all number
    26
    34
    0
    Hypophosphataemia
         subjects affected / exposed
    9 / 338 (2.66%)
    45 / 324 (13.89%)
    0 / 10 (0.00%)
         occurrences all number
    21
    78
    0
    Hypoproteinaemia
         subjects affected / exposed
    9 / 338 (2.66%)
    10 / 324 (3.09%)
    0 / 10 (0.00%)
         occurrences all number
    12
    12
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    01 Sep 2017
    The primary purpose of this amendment was to incorporate feedback from regulatory authorities, align the protocol with the Sponsor’s new protocol template, clarify items that were inconsistent in the original protocol, and add the new safety run-in substudy for the assessment of preliminary safety in Japanese patients with previously treated HCC. No patient was enrolled under Protocol Amendment 1.0. The major protocol changes and rationale for these changes were as follows: • Changed objectives/endpoint: to reflect the testing procedure described in the protocol and importance of efficacy endpoints, ORR was moved from primary to secondary objective, and DCR and CBR were moved from exploratory objective to secondary objective. • Added the safety run-in substudy to the study design to provide a preliminary safety assessment in Japanese patients prior to enrollment in randomized portion of the Phase 3 study (tislelizumab had not previously been administered in Japanese patients). • Modified inclusion criterion to reflect the PMDA’s request to only enroll Japanese patients who have been previously treated in the safety run-in substudy. • Modified inclusion criterion to include only patients with Child Pugh A liver function for best assessment of effect in experimental arms. • Modified stratification factors at randomization to balance the two treatment arms: removed Child Pugh classification (Class A versus Class B); split extrahepatic spread (present versus absent) and macrovascular invasion (present versus absent) into 2 separate strata; added etiology and ECOG. • Modified inclusion criterion to include patients with moderate renal impairment (creatinine clearance ≥ 30 mL/min by estimated glomerular filtration rate). • Modified inclusion criterion to enroll patients with better liver synthetic function. • Modified inclusion criteria to avoid enrollment of any patients who may be concurrently pregnant.
    03 Oct 2017
    The primary purpose of this amendment was to incorporate feedback from the BGB-A317-301 steering committee that further refined study eligibility to (1) avoid barriers to enrollment and (2) exclude patients whose underlying medical condition or disease status would be unfavorable for the administration of study drug. It also clarified the safety management of immune-mediated adverse events (imAEs) and any inconsistencies between the main protocol and the Japan safety run-in substudy protocol. No patient was enrolled under Protocol Amendment 2.0. The major protocol changes and rationale for these changes were as follows: • Modified inclusion criterion and removed requirement for continuous HCV treatment to align as per recommendation from American Association for the Study of Liver Disease on the treatment and management of patients with HCV infection. • Modified exclusion criterion to exclude enrollment of patients whose underlying medical condition or disease status would have been unfavorable for the administration of study drug. • Modified exclusion criterion since extrahepatic spread of HCC to the central nervous system is very uncommon and assessment with MRI/CT scan ought to be conducted based on clinical signs/symptoms.
    18 Oct 2017
    The primary purpose of this amendment was to incorporate feedback from the FDA regarding safety monitoring for potential imAEs after administration of BGB-A317. The major protocol changes and rationale for these changes were as follows: • Removed the statement that follow-up of all drug-related SAEs and imAEs be stopped at initiation of subsequent anticancer therapy to be able to capture all possible delayed imAEs. The protocol was modified to ensure that the safety follow-up period was ≥ 90 days for all patients on the BGB-A317 arm, regardless of initiation of subsequent anticancer therapy. • Added eye exams and visual acuity testing conducted by a specialist at baseline and every 4 months for all patients, inclusive of optical coherence tomography or an appropriate similar diagnostic test to monitor for potential ocular toxicities that have been associated with PD-1 inhibitors as a class.
    28 Jun 2018
    The primary purpose of this amendment was to merge language from the country-specific Protocol Amendments 3.1 (Japan) and 3.4 (Germany), as well as to incorporate feedback from the FDA. The major protocol changes and rationale for these changes were as follows: • Incorporated changes from the Japan specific amendment 3.1 in the Japan substudy based on feedback from the Japan PMDA (details are provided below in the description of Protocol Amendment 3.1) • Incorporated changes from the Germany-specific Protocol Amendment 3.4 in the main study from the Paul-Ehrlich-Institut (details are provided below in the description of Protocol Amendment 3.4) • Incorporated measures to further decrease the potential risk for hepatitis viral reactivation based on feedback from the FDA • Added a new appendix which specified Chinese herbal medications that were not allowed during study treatment
    11 May 2020
    The primary purpose of this amendment was to revise the statistical assumptions (ie, HR, stopping boundaries) for the interim analysis of the primary endpoint (OS) based on available published data. Based on the revised assumptions, the timing for the interim analysis of OS was delayed from 75% (ie, 378 deaths) until approximately 80% (ie, 403 deaths) of the targeted number of OS events (approximately 504 deaths) had occurred. The planned futility analysis at interim was removed.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references

    http://www.ncbi.nlm.nih.gov/pubmed/30969136
    http://www.ncbi.nlm.nih.gov/pubmed/37796513
    http://www.ncbi.nlm.nih.gov/pubmed/39435268
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 22:47:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA